

SENATE CONCURRENT RESOLUTION NO. 19

Whereas, rising health care costs remain a significant concern for Missouri families, employers, and communities, and improving affordability is a top priority for all Missourians and Americans; and

Whereas, American patients have subsidized innovation and low-cost prescription drugs for wealthy foreign countries who must start to pay their fair share; and

Whereas, President Donald J. Trump has taken creative actions aimed at improving the affordability of health care for Missourians and all Americans while protecting U.S. leadership in global medical innovation and investment in research and development; and

Whereas, the Trump Administration intends to leverage federal trade authorities to ensure foreign nations pay more for prescription drugs and announced agreements to bring lower medicine prices to U.S. patients; and

Whereas, on September 30, 2025, President Trump announced TrumpRx, an online direct-purchasing platform that aims to connect U.S. patients with lower prices for their prescription medications, increase transparency, and bypass supply chain middlemen; and

Whereas, it is essential that Missouri patients who choose to secure their medications through TrumpRx do not forfeit access to the health plan benefits that they already pay for; and

Whereas, Missourians who use TrumpRx could be steered back to higher-cost channels if their cash-pay expenses are not applied toward their health plan deductibles and out-of-pocket maximums; and

Whereas, safeguarding health insurance coverage and ensuring parity for all patient out-of-pocket prescription drug costs would promote market competition and complement the Trump Administration's efforts to improve affordability; and

Whereas, on November 6, 2025, the Centers for Medicare and Medicaid Services announced the GENERating cost Reductions fOr U.S. Medicaid (GENEROUS) Model to enable state Medicaid programs to voluntarily access lower drug prices through federally-negotiated supplemental rebates; and

Whereas, the GENEROUS Model may offer Missouri and MO HealthNet a pathway to achieve significant cost savings from federal agreements:

Now, Therefore, Be It Resolved, that the members of the Missouri Senate, One Hundred and Third General Assembly, Second Regular Session, the House of Representatives concurring therein, hereby express support for TrumpRx and encourage the U.S. Department of Health and Human Services to act to prevent against discriminatory insurance practices and require health insurance plans and pharmacy benefit managers to apply all patient-paid prescription drug expenditures, including those obtained through TrumpRx and similar direct-purchasing platforms, toward patients' cost-sharing requirements, such as deductibles and out-of-pocket maximums; and

Be It Further Resolved, the Missouri General Assembly strongly urges health insurers and pharmacy benefit managers to announce that they will apply all patient-paid prescription drug expenditures, including those obtained through TrumpRx and similar direct-purchasing platforms, toward patients' cost-sharing requirements, such as deductibles and out-of-pocket maximums; and

Be It Further Resolved, the Missouri General Assembly requests that the Missouri Department of Social Services assess the GENEROUS Model, and report and remove any barriers that would prevent or delay MO HealthNet's participation, to ensure that Missouri can realize potential cost savings; and

Be It Further Resolved, that the Secretary of the Senate be instructed to prepare a properly inscribed copy of this resolution for each member of the Missouri Congressional delegation, the Director of the Department of Social Services, the U.S. Department of Health and Human Services, and the White House.